Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
2.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Review.

PMID:
25116092
3.

JAK2 and MPL mutations in myeloproliferative neoplasms.

Koppikar P, Levine RL.

Acta Haematol. 2008;119(4):218-25. doi: 10.1159/000140634. Epub 2008 Jun 20. Review.

PMID:
18566540
4.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22. Review.

PMID:
18496562
5.

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

Vainchenker W, Kralovics R.

Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27. Review.

PMID:
28028029
6.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
7.

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.

Tefferi A.

Am J Hematol. 2016 Jan;91(1):50-8. doi: 10.1002/ajh.24221. Review.

8.
9.

Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?

Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.

Asian Pac J Cancer Prev. 2016;17(3):923-6. Review.

10.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
11.

[Research progress on molecular pathogenesis of myeloproliferative neoplasms].

Liu L, Xiao ZJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Feb;19(1):239-43. Review. Chinese.

PMID:
21362261
12.

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.

Plo I, Vainchenker W.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S329-39. doi: 10.3816/CLM.2009.s.032. Review.

PMID:
19778861
13.
14.

Molecular genetic evaluation of myeloproliferative neoplasms.

Azzato EM, Bagg A.

Int J Lab Hematol. 2015 May;37 Suppl 1:61-71. doi: 10.1111/ijlh.12353. Review.

PMID:
25976962
15.
16.

Myeloproliferative neoplasms: Current molecular biology and genetics.

Saeidi K.

Crit Rev Oncol Hematol. 2016 Feb;98:375-89. doi: 10.1016/j.critrevonc.2015.11.004. Epub 2015 Nov 28. Review.

PMID:
26697989
17.

Aberrant signal transduction pathways in myeloproliferative neoplasms.

Kota J, Caceres N, Constantinescu SN.

Leukemia. 2008 Oct;22(10):1828-40. doi: 10.1038/leu.2008.236. Epub 2008 Sep 4. Review.

PMID:
18769448
18.

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.

Oh ST, Gotlib J.

Expert Rev Hematol. 2010 Jun;3(3):323-37. doi: 10.1586/ehm.10.28. Review.

PMID:
21082983
19.

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.

Pikman Y, Levine RL.

Curr Opin Oncol. 2007 Nov;19(6):628-34. Review.

PMID:
17906464
20.

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

Tefferi A, Vainchenker W.

J Clin Oncol. 2011 Feb 10;29(5):573-82. doi: 10.1200/JCO.2010.29.8711. Epub 2011 Jan 10. Review.

PMID:
21220604

Supplemental Content

Support Center